Industry
Life sciences
A promising asset still dies in the handoff between research, development, manufacturing, and the people who have to adopt it.
What is changing
- Portfolios are wide, and the cash to carry them all is not.
- Manufacturing and quality are on the critical path earlier than the old model assumed.
- Payers and clinicians ask for evidence that arrives late in the plan.
How we work here
We help leadership teams concentrate the portfolio and line up development, supply, and the launch story. The point is a medicine that can be made, approved, and used.
Related capabilities